Navigation Links
Access Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference on Monday, September 12th in New York City
Date:9/6/2011

DALLAS and NEW YORK, Sept. 6, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that the Company's management team will present at the Rodman & Renshaw Annual Healthcare Conference on Monday, September 12th at 2:25p.m., in the Metropolitan West Room at the New York Palace Hotel.  Jeffrey Davis, Chief Executive Officer of Access Pharmaceuticals, will give a presentation focused on the Company's lead product for oral mucositis, MuGard and detail the development strategy for ongoing programs within its drug pipeline.  

A live webcast of the presentation may be accessed by clicking on the following link: http://www.wsw.com/webcast/rrshq20/accp  .To arrange a meeting with Access management at the conference, please email Christine Berni, christine.berni@accesspharma.com.

Conference Call Reminder:The investor conference call is scheduled to be held tomorrow, Wednesday, September 7, 2011 at 11:00 am EDT.  Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time. A replay of the call will be available starting on September 7th at 1:00 pm EDT, through September 21, 2011 until 11:59 pm EDT.  Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 377785.

About MuGard:MuGard is a novel; ready-to-use mucoadhesive oral wound rinse a
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced a new ... in portable vaporizers, which contains CBD, or cannabodiol. ... cannabidiol offers consumers a THC-free product made for ... technology. Photo - http://photos.prnewswire.com/prnh/20140711/126344 ... compounds which are currently known, two of which ...
(Date:7/11/2014)... July 11, 2014 The consumer marketing ... across industry sectors to better identify winning tools ... to engage with and understand consumers, as new ... make critical purchasing decisions. According ... LLC, one area where organizations can observe a ...
(Date:7/11/2014)... 11, 2014 Research and Markets ... Chinese Medical X-ray Film Industry Report 2014" report ... Global And Chinese Medical X-Ray Film ... on the current state of the Global medical X-ray ... The report provides a basic overview of the ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Technologies Transforming Consumer Marketing Research Playbook 2Global and Chinese Medical X-ray Film Industry Report 2014 2
... WELLESLEY, Mass., Oct. 26 Coley,Pharmaceutical Group, Inc. ... company,has received a $3.0 million milestone payment from ... III clinical trial in,non-small cell lung cancer (NSCLC) ... adjuvant. In June 2007, GSK announced the ...
... at AACR-NCI-EORTC ... Symposium, ... MTAX: CTIC) and Systems Medicine, LLC (SM), a,wholly-owned subsidiary of CTI, ... 19th annual AACR-NCI-EORTC Symposium. "These studies show potential progress toward ...
Cached Medicine Technology:Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline 2Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 2Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 4Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 5
(Date:7/13/2014)... According to a new market research report ... (processor, GPU, DSP, connectivity), Technology Node (45nm-5nm), Application ... Forecast and Analysis to 2014-2020", published by MarketsandMarkets, ... is expected to reach $61.70 Billion by 2020, ... to 2020. , Browse 71 market data Tables ...
(Date:7/13/2014)... 13, 2014 A Massachusetts couple who ... cancer risks associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) ... to federal regulators, as they presented poignant testimony on ... Drug Administration (FDA) advisory panel meeting convened to address ... the Rochester Democrat and Chronicle, Dr. Hooman Noorchashm and ...
(Date:7/13/2014)... 2014 The Pearland, Texas location of The ... from four months to 12 years of age that offers ... birthday parties and Summer Camps, is now under new ownership. ... Pearland after spending over six years at The Little ... Director. , Berry has over ten years of experience ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 The federal ... ) filed against Johnson & Johnson’s Ethicon, ... trial, which is expected to get underway next month. ... the U.S. District Court, Southern District of West Virginia ... held on August 7, 2014 at 3:00 p.m. July ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Max ... Famer, Chris Mullin, will be the featured guest at ... 26th in Puerto Rico. Attendees will learn about ... participate in two exhibition basketball games and perform in ... supplier of health- and energy-boosting supplements , has ...
Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4
... , , , ... http://www.avacor.com ) has acquired the assets ... name; Avacor,s FDA approved Physicians, Topical Formulation(R); the All-Natural Nutricap and ... Application) which allows the company to market and sell the FDA ...
... Going out like a brilliant flame is one way ... a form of programmed suicide called apoptosis, a desired effect ... could more quickly pick the most effective treatment. Now scientists ... way to do just that, by lighting up cells as ...
... A new study by researchers from the Automotive Safety Program ... Medicine published online July 13, 2009 in the journal ... health care needs are doing a good job with the ... help in using it correctly. The study, one of ...
... to aid in understanding childhood brain development and healthy ... Deficit Hyperactivity Disorder and detecting the early onset of ... million in recent funding from the Canadian Institutes of ... makes us human is the ability to control our ...
... , , WASHINGTON, July 13 ... creation of a National Diabetes Coordinator to develop and implement a nationwide ... , , A study commissioned by NCDP ... The coordinator would be responsible for establishing priorities in the fight ...
... , , , WASHINGTON, ... in Congress, the Institute for America,s Future today released the names ... All the experts favor a public health insurance option to compete with ... to the health care debate. , , ...
Cached Medicine News:Health News:Avacor(R), Premier Provider of Hair Growth Solutions, Acquired By Investor Group. 2Health News:Fluorescent probes may permit monitoring of chemotherapy effectiveness, Stanford study shows 2Health News:Fluorescent probes may permit monitoring of chemotherapy effectiveness, Stanford study shows 3Health News: Making the difficult task of transporting a child with special needs safer 2Health News:Queen's University study aims at early diagnosis for ADHD and Parkinson's disease 2Health News:Diabetes Advocates Call For National Strategy, Leadership to Reduce Diabetes and Advance Detection and Treatment 2Health News:Diabetes Advocates Call For National Strategy, Leadership to Reduce Diabetes and Advance Detection and Treatment 3Health News:Diabetes Advocates Call For National Strategy, Leadership to Reduce Diabetes and Advance Detection and Treatment 4Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 2Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 3Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 4Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 5
Inquire...
Integrated closure system provides security you can feel as the plastic fasteners lock into place and is both easy to close, empty and clean....
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies....
Inquire...
Medicine Products: